12 unknown, 10 completed, 9 active not recruiting, 4 recruiting. 23 Phase 2, 13 Phase 3, 7 Phase 1, 2 Not applicable, 2 Phase 4.
Follow R-CHOP protocol: new trials by email Literature Review of R-CHOP protocol trials Research Report on R-CHOP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL Celecoxib Combined with R-CHOP, R-CHOP - Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive | Phase 2 | Recruiting | Sun Yat-sen University | 60 | 2026-03-06 | 2026-07-22 |
| Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study R-CHOP, POLA-R-CHP, Lisaftoclax - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Sun Yat-sen University | 122 | 2026-02-28 | 2026-02-10 |
| Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL ZCR-CHOP, R-CHOP - BTK Inhibitors, Histone Deacetylase Inhibitor | Phase 2 | Not yet recruiting | Li Zhiming | 128 | 2025-06-01 | 2025-03-24 |
| Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial) Orelabrutinib Oral Tablet, R-CHOP Protocol - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Recruiting | Sun Yat-sen University | 39 | 2024-11-01 | 2024-10-22 |
| A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients Surovatamig, R-CHOP, R-CVP - Untreated Follicular Lymphoma | Phase 3 | Recruiting | AstraZeneca | 1018 | 2024-08-07 | 2026-10-21 |
| Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) Selinexor Oral Tablet [Xpovio], R-CHOP Protocol - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Sun Yat-sen University | 42 | 2024-08-01 | 2026-02-12 |
| A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma R-CHOP, Decitabine in combination with R-CHOP - Lymphoma, Large-Cell, Diffuse | Phase 3 | Enrolling by invitation | Second Affiliated Hospital of Nanchang University | 80 | 2024-07-01 | 2026-01-16 |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 109 | 2023-10-02 | 2026-04-17 |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 54 | 2022-11-01 | 2023-12-14 |
| A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma Orelabrutinib and R-CHOP, R-CHOP - Treatment-naїve Mantle Cell Lymphoma | Phase 3 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 3 | 2021-12-22 | 2026-03-31 |
| Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A) - Follicular Lymphoma | Phase 3 | Active not recruiting | Fondazione Italiana Linfomi - ETS | 605 | 2021-12-01 | 2026-06-26 |
| Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL) R-CHOP, R-CHOP + acalabrutinib - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | University Hospital Southampton NHS Foundation Trust | 453 | 2021-10-19 | 2026-04-30 |
| Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma Acalabrutinib, R-CHOP chemotherapy - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | University Health Network, Toronto | 105 | 2021-03-01 | 2026-06-12 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) tafasitamab, lenalidomide, parsaclisib - Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Incyte Biosciences Japan GK | 72 | 2020-12-15 | 2026-10-21 |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 543 | 2020-11-03 | 2026-11-03 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) Epcoritamab (monotherapy), Epcoritamab, Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Genmab | 78 | 2020-08-20 | 2026-11-04 |
| PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients Vincristine Sulfate Liposome, CHOP, R-CHOP - Hematologic Diseases | Phase 1 | Unknown | Acrotech Biopharma Inc. | 56 | 2020-08-15 | 2020-04-16 |
| Copanlisib in Combination With Rituximab and CHOP Chemotherapy in Patients With Previously Untreated DLBCL Copanlisib, R-CHOP Chemotherapy - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | University Hospital Muenster | 62 | 2020-06-19 | 2026-07-30 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma Pembrolizumab, R-CHOP Protocol - B Cell Lymphoma, Lymphoma | Phase 2 | Active not recruiting | University of Chicago | 51 | 2019-08-29 | 2025-06-08 |
Showing 20 of 42. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (22) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma (5) · Pyloric Stenosis, Hypertrophic (2) · HIV Infections (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large-Cell, Anaplastic (1) · Nausea (1) · Recurrence (1)
Sun Yat-sen University (5) · European Mantle Cell Lymphoma Network (2) · Fondazione Italiana Linfomi - ETS (2) · Fudan University (2) · Genmab (2) · AHS Cancer Control Alberta (1) · Acrotech Biopharma Inc. (1) · Asan Medical Center (1) · AstraZeneca (1) · Australasian Leukaemia and Lymphoma Group (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · CTI BioPharma (1) · Dana-Farber Cancer Institute (1) · Heidelberg University (1) · Huiqiang Huang (1)
China (14) · Germany (8) · United States (7) · France (6) · Italy (6) · Canada (5) · Poland (5) · Spain (5) · Czechia (4) · Australia (3) · Belgium (3) · Denmark (3) · Japan (3) · Netherlands (3) · South Korea (3)
Andrew Davies (1) · Andrew Grigg, Professor (1) · Anita Kumar, MD (1) · Anthony D. Ho, Ph.D., Prof. (1) · Chan Cheah, MBBS FRACP FRCPA DMSc (1) · Douglas Stewart, M.D. (1) · Fang-Fang Lv (1) · Gabor Jurida, M.D. (1) · Hagop Youssoufian, MD (1) · Hanneke C. Kluin-Nelemans, PhD (1) · Ho-Jin Ho-Jin (1) · Johanna Cornelia Kluin-Nelemans, Prof. Dr. (1) · Jun Zhu, MD (1) · Justin Kline, MD (1) · Martin Dreyling, PhD (1)
PMID 20032498, PMID 24687837, PMID 19863177, PMID 20644097, PMID 22873532, PMID 23946328, PMID 25559471, PMID 25596266, PMID 26022239, PMID 27313086, PMID 29095677, PMID 29750632, PMID 30125215, PMID 31710995, PMID 31804876, PMID 32022621, PMID 33928400, PMID 34022150, PMID 34708297, PMID 34788401, PMID 35418080, PMID 36469833, PMID 37992261, PMID 39792928, PMID 40397196, PMID 40453056, PMID 40632620, PMID 40920572, PMID 41563911, PMID 41784015, PMID 42411504, PMID 42541678, PMID 42622258, PMID 42660129
2023 (3), 2015 (1), K01TW009488 (1), R21CA180815 (1)